Zai Lab Announces NDA Acceptance of Margetuximab for Patients with Pretreated Metastatic …

SHANGHAI and SAN FRANCISCO and CAMBRIDGE, Mass., Jan. 06, 2022 (GLOBE NEWSWIRE) — Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today announced that